TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07700966: A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing S

Sponsor: Abeona Therapeutics, Inc · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 250 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07700966 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07700966 Rescue Dossier →